Memorandum

Bigfoot adds new commercial team leadership in preparation for first-gen Unity launch – December 11, 2020

SVP Berkley Nelson, VP of Sales Tony Galliani, and Director of Commercial Operations Sam Auderer bring experience from Companion Medical, Medtronic, Voluntis, and more

Bigfoot Biomedical announced three significant new hires this week, expanding the company’s commercial team ahead of the anticipated FDA clearance and launch of the first-gen Unity system. The Unity system, which includes FreeStyle Libre 2, Bigfoot’s smart pen caps for basal and rapid-acting insulins, pen needles, a backup BGM and supplies, a mobile app as well as “real-time decision support” on the pen cap displays, was submitted to the FDA in July. See our interview with Bigfoot CEO Dr. Jeffrey Brewer for more.

  • Mr. Berkley Nelson will serve as Senior Vice President lead the commercial team. Bigfoot’s announcement notes that Mr. Nelson will “shape Bigfoot’s commercialization approach with responsibility for leading the team when they begin to contract with health care providers and payers.” Immediately prior to Bigfoot, Mr. Nelson served as Chief Growth Officer for insulin titration company Voluntis. Mr. Nelson has also served as VP of Payer Relations at United Allergy Services and VP of Health Plan Sales at Medtronic’s Cardiocom.

  • Mr. Tony Galliani will serve as Vice President of Sales. His role at Bigfoot will focus on “health care provider sales.” Mr. Galliani has valuable experience in the smart pen space - Mr. Galliani was previously the VP of Sales at Companion Medical (acquired by Medtronic in August) and has also been part of the sales teams at Tandem and J&J’s Animas.

  • Mr. Sam Auderer will serve as Director of Commercial Operations. Like Mr. Nelson, Mr. Auderer has previously worked at Voluntis and United Allergy Services. Immediately prior to Bigfoot, Mr. Auderer worked as the Director of Commercial Operations at Voluntis.

 

--by Albert Cai and Kelly Close